Innovation in the management of severe equine asthma didn’t exist – until now.

Key Feature #1:
Contains a novel glucocorticoid (ciclesonide) that is 12x more potent than dexamethasone when activated in the respiratory tract.

Its Benefit:
ASERVO EQUIHALER was proven to be an effective treatment option with lower risk of side effects due to no significant cortisol suppression compared to the most common alternative glucocorticoid treatment (dexamethasone).

Key Feature #2:
Uses the Soft Mist Technology

Its Benefit:
An advanced inhalation technology (Soft Mist™ Inhaler) that delivers medication deep into the peripheral lung.

Key Feature #3:
A dosing system with a horse-designed nostril adapter

Its Benefit:
ASERVO EQUIHALER is designed to precisely and consistently deliver a predetermined dose of ciclesonide with each actuation and accepted by >93% of horses.

IMPORTANT SAFETY INFORMATION: ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares. In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing, and nasal irritation/bleeding. Administration of corticosteroids may worsen existing bacterial, fungal, or viral infection and may induce the first stage of parturition. Glucocorticoids should be used with caution in horses at a higher risk for laminitis. Do not use in horses with known hypersensitivity to ciclesonide or corticosteroids. Not for use in humans. Keep this and all medications out of the reach of children. In case of accidental inhalation, seek medical advice immediately. Information for Horse Owners: After veterinary consultation, please read and understand the entire contents of the user manual for instructions regarding proper handling and use of ASERVO EQUIHALER.

References

ASERVO® and EQUIHALER® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trademarks are property of their respective owner. ©2020 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0282-2020
Aservo® Equihaler® (ciclesonide inhalation spray) the first FDA-approved inhalant glucocorticoid for horses that is proven to improve lung function with a 10-day treatment protocol.¹

**TREATMENT DURATION** 10 DAYS

**TREATMENT DAYS 1-5:**

8 PUFFS 2X PER DAY

**TREATMENT DAYS 6-10:**

12 PUFFS 1X PER DAY

For more information about this innovative severe equine asthma treatment visit AservoEquihaler.com

**IMPORTANT SAFETY INFORMATION:** ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares. In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing and nasal irritation/bleeding. Glucocorticoids should be used with caution in horses at a higher risk for laminitis. Not for use in humans. Keep this and all medications out of the reach of children.

ASERVO® and EQUIHALER® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trademarks are property of their respective owner. ©2020 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0282-2020

**References**


**sound byte**

**CONFIDENCE**

I believe ASERVO EQUIHALER is safe and effective for managing the clinical signs associated with severe equine asthma.

**NEUTRAL INVITATION**

Let’s take a look at some of the unique and innovative features of ASERVO EQUIHALER

**IT’S THE CUSTOMER’S DECISION**

...so you can decide whether ASERVO EQUIHALER is an important solution you’ll consider for your equine patients presenting with signs of severe equine asthma.

First, always ask if a Boehringer Ingelheim representative has been in contact recently:

**Doctor, have you recently been introduced to ASERVO EQUIHALER?**

If **YES**, confirm and discuss benefits.

If **NO**, engage/detail the customer as the primary contact.